Barrière Launches World’s First Lactose-Intolerance Patch and Expands Wearable Supplement Line

Barrière introduced Dear Dairy, a transdermal patch delivering a 2.5 mg dose of lactase enzyme to alleviate dairy-intolerance symptoms. The patch is applied to clean, dry skin 30 minutes before the first bite of dairy and can provide up to 12 hours of relief. Each pack of 36 patches retails for $13 and is offered in “Milky Way” neutral prints or “Milky Treats” designs featuring ice-cream and coffee motifs.

WWDCNBC

The U.S. supplement market, valued at $60 billion with more than 100,000 products, is projected to grow 11 % by 2027. Vitamin sales rose from roughly $14 billion in 2021 to over $17 billion in 2025, and unit sales increased nearly 5 % between 2024 and 2025. Younger consumers, especially Generation Z, are drawn to the convenience and marketing of wearable patches, a trend noted by pharmaceutical-sciences professor Mahtab Jafari.

CNBC

Founded in 2020, Barrière entered mainstream retail through Target, Ulta Beauty, and, as of early 2026, 1,700 Walmart stores. CEO and co-founder Cleo Davis-Urman projects revenue to double from 2025, reaching $10 million in 2026, with a current valuation of $19 million. The company reported a 3,000 % jump in wholesale monthly dollar volume in 2025. Patch packs are priced between $13 and $18 for a month’s supply.

CNBC

Barrière’s patches are styled with floral or jewel motifs to make supplementation “fun, enjoyable and convenient.” A two-week, in-home study of 83 participants found that 76 % reported less cramping and over 85 % experienced little or no discomfort two to four hours after dairy consumption. The company expects Dear Dairy to generate roughly $1 million in sales by the end of 2026.

WWD

Davis-Urman emphasized that Barrière manufactures its patches in the United Kingdom because “the strictest regulations possible” apply there, positioning the brand as transparent and health-focused. She noted that the FDA classifies supplements as food, not drugs, leaving marketing largely to companies. Barrière’s expansion into Walmart and its projected revenue growth are presented as evidence of strong consumer demand for “stylish, easy-to-wear” wellness solutions.

CNBC

Barrière’s products are not FDA-approved, and the agency’s oversight of dietary supplements is limited. Critics point out that “marketing is usually way ahead of science,” raising questions about the scientific validation of transdermal lactase delivery beyond the company-run study. The lack of independent efficacy data and the reliance on consumer-driven marketing are noted as potential consumer-protection issues.

CNBC

Other wellness-patch brands such as PatchMD, PatchAid, and vitamin-focused company Thorne remain concentrated on vitamin delivery. Barrière’s NAD+ patch, launched after celebrity promotion, became its best-selling product, encouraging the firm to explore non-vitamin categories.

WWD

The company plans additional non-vitamin patches for launch in the second half of 2026, aiming to broaden its R&D pipeline beyond vitamins and further capitalize on the wearable-supplement trend.

CNBC

• “Transparency is key, education is key and, in some ways, being made in the U.K. does signal to a discerning wellness customer that there are more measures put into place to protect their health and wellness,” — Cleo Davis-Urman, CEO & Co-founder

CNBC

• “The idea with this product is that you don’t have to make it complicated to enjoy dairy,” — Cleo Davis-Urman, Co-founder

WWD

• “[Dear Dairy] gives people the freedom to be spontaneous, and hopefully can make a meaningful impact on their day-to-day lives,” — Cleo Davis-Urman, Co-founder

WWD

• “I always say that marketing is usually way ahead of science, so marketing is a key factor," Jafari told CNBC.” — Mahtab Jafari, Professor of Pharmaceutical Sciences, UC Irvine

CNBC

• “It doesn't sort of disappear in the sea of sameness like so many of the clinical science lab solutions in the supplement space,” — Cleo Davis-Urman, CEO & Co-founder

CNBC

Barrière’s efficacy claims rely on an internal consumer study; no independent clinical trials have been cited. The FDA’s limited regulatory role means the patches are marketed without formal approval, creating a gap between consumer expectations and verified safety data.

CNBC